Stroke Disorder Treatment Market

Increasing number of stroke patients to boost market growth

The rising number of stroke patients is a key factor driving the growth of the stroke treatment market. Stroke is a major health problem that affects millions of people worldwide, and it is a leading cause of disability and death. According to the World Stroke Organization, stroke is the second leading cause of death and the third leading cause of disability globally. As the global population continues to age, the prevalence of stroke is expected to increase.

The World Health Organization estimates that the number of stroke cases worldwide will increase by 25% over the next 20 years, with the greatest increases expected in low- and middle-income countries. In addition to aging, other risk factors for stroke include hypertension, diabetes, smoking, and high cholesterol, among others. As these risk factors continue to be prevalent, the number of stroke cases is likely to increase further. According to Centers for Disease Control and Prevention (CDC), In 2019, stroke was the fifth leading cause of death in the United States, with over 147,000 deaths attributed to stroke.

Also, in 2018, over 795,000 people in the US had a stroke, with 610,000 of these being first-time strokes.

The rising number of stroke patients is driving demand for effective stroke treatment options, including medications, medical devices, and rehabilitation therapies. Pharmaceutical companies are investing in the development of new stroke treatments, while medical device manufacturers are developing innovative devices for use in stroke treatment and prevention. In addition, rehabilitation centers are expanding their services to meet the needs of stroke patients, offering a range of therapies to help patients recover and regain their independence.

However, another major driver of the market during the forecast period are the increase in the elderly population, chronic diseases, neurological disorders, etc. The market is also growing as a result of numerous symptoms like tiredness, dilated pupils, impaired vision, losing balance when walking, paralysis, and stiff neck. Moreover, an unhealthy diet, an increase in alcohol use, a rise in smoking, and an increase in the number of diabetics are all factors that will affect market growth in the near future.

Peripheral neuropathy is thought to account for 46.2% of the total 3000 people, chronic headaches for 26.4%, epilepsy for 8.5%, stroke for 6.6%, and tremors/disease Parkinson's for 3.8%, according to BMC Neurology study. Also, the market will rise during the forecast period due to technical developments along with manufacturer research and development efforts to provide new advanced technological devices and medications for people suffering from strokes. Similar to this, the government's growing efforts to raise public awareness through organizations like the American Heart Association, CDC, and WHO are also focusing on market expansion.

The demographic shift towards an aging population is a critical driver of the Global Stroke Disorder and Treatment Market Industry. As individuals age, the risk of stroke increases, leading to a higher demand for stroke-related healthcare services. The United Nations projects that the global population aged 60 years and older will reach 2.1 billion by 2050. This demographic trend suggests a growing need for effective stroke prevention and treatment strategies. Consequently, healthcare systems must adapt to accommodate this aging population, further propelling the market's growth trajectory in the coming years.

The Global Stroke Disorder and Treatment Market Industry is poised for substantial growth, with projections indicating a market value of 23.9 USD Billion in 2024 and an anticipated increase to 49.6 USD Billion by 2035. This growth trajectory, characterized by a compound annual growth rate (CAGR) of 6.88% from 2025 to 2035, reflects the increasing demand for effective stroke treatments and interventions. Factors such as rising incidence rates, technological advancements, and enhanced healthcare initiatives contribute to this optimistic outlook. The market's expansion signifies a critical opportunity for stakeholders to invest in innovative solutions and improve patient outcomes.

The Global Stroke Disorder and Treatment Market Industry is experiencing growth due to the increasing incidence of stroke worldwide. According to the World Health Organization, stroke is a leading cause of death and disability globally, with an estimated 15 million people suffering from strokes each year. This rising prevalence necessitates enhanced treatment options and healthcare services, contributing to the market's expansion. The financial implications are substantial, with the market projected to reach 23.9 USD Billion in 2024, indicating a pressing need for innovative therapies and interventions to address this growing health crisis.

Heightened awareness and education regarding stroke symptoms and risk factors are influencing the Global Stroke Disorder and Treatment Market Industry positively. Public health campaigns aimed at educating individuals about the signs of stroke and the importance of timely intervention have led to earlier diagnosis and treatment. For example, initiatives by organizations such as the American Stroke Association have significantly improved public knowledge. This increased awareness is likely to result in more individuals seeking treatment, thereby driving market growth. The projected CAGR of 6.88% from 2025 to 2035 reflects the potential for continued expansion in response to these educational efforts.

Government initiatives and funding for stroke research and treatment are crucial drivers of the Global Stroke Disorder and Treatment Market Industry. Many countries are implementing national stroke strategies aimed at improving prevention, treatment, and rehabilitation services. For instance, the National Institutes of Health in the United States allocates substantial resources to stroke research, fostering innovation in treatment approaches. Such initiatives not only enhance healthcare infrastructure but also stimulate market growth by encouraging the development of new therapies. As governments prioritize stroke care, the market is expected to benefit significantly from increased funding and support.

Technological advancements play a pivotal role in shaping the Global Stroke Disorder and Treatment Market Industry. Innovations such as minimally invasive surgical techniques, advanced imaging technologies, and novel pharmacological agents are revolutionizing stroke management. For instance, the development of thrombolytic agents has significantly improved outcomes for ischemic stroke patients. As these technologies continue to evolve, they enhance the efficacy of treatments, thereby attracting investments and driving market growth. The anticipated market value of 49.6 USD Billion by 2035 underscores the potential impact of these advancements on patient care and recovery.

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Stroke Disorder and Treatment market accounted for USD 9.39 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period.

This is attributed to an increase in the prevalence of chronic diseases like diabetes, a surge in the demand for stroke management devices, the availability of government healthcare facilities with skilled medical personnel, an increase in the number of R&D activities along with the significant participation of key players, and an increase in government investment in the healthcare system.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: STROKE DISORDER AND TREATMENT MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe stroke disorder and treatment market accounts for the second-largest market share due to enhanced healthcare infrastructure, greater per capita income, and increased health awareness. Further, the Germany stroke disorder and treatment market held the largest market share, and the UK stroke disorder and treatment market was the fastest growing market in the European region

The Asia-Pacific Stroke Disorder and Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to improvements in the healthcare infrastructure, an increase in the number of hospitals using cutting-edge technology, the growth of the R&D industry, a rise in healthcare reforms, and developments in the field of stroke management technology. Moreover, China stroke disorder and treatment market held the largest market share, and the India stroke disorder and treatment market was the fastest growing market in the Asia-Pacific region

Major market players are spending a lot of money on R&D to increase their product lines, which will help the stroke disorder and treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the stroke disorder and treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global stroke disorder and treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, stroke disorder and treatment industry has provided medicine and treatment with some of the most significant benefits. The stroke disorder and treatment market major player such as Novartis AG, Astra Zeneca, Bayer Pharma AG and others are working to expand the market demand by investing in research and development activities.

Novartis AG is a Swiss multinational pharmaceutical company that develops and produces a wide range of pharmaceuticals, including prescription drugs, over-the-counter medications, and generics. The company was founded in 1996 through the merger of Ciba-Geigy and Sandoz and is headquartered in Basel, Switzerland. Novartis AG's product portfolio includes drugs for various therapeutic areas, including cardiology, oncology, neurology, dermatology, ophthalmology, respiratory, and immunology. Some of the company's most well-known products include Diovan, Gilenya, Lucentis, and Cosentyx. In March 2019, Novartis announced positive results from its Phase III clinical trial of canakinumab, a drug that reduces inflammation in the body.

The trial showed that canakinumab can reduce the risk of cardiovascular events, including stroke, in patients with a history of heart attack.

Also, Bayer Pharma AG is a German multinational pharmaceutical company that produces and develops a wide range of products, including prescription and over-the-counter medications, medical devices, and agricultural chemicals. The company was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Pharma AG's product portfolio includes drugs for various therapeutic areas, including cardiology, oncology, hematology, ophthalmology, pulmonology, and women's health. Some of the company's most well-known products include Aspirin, Xarelto, Eylea, and Yasmin. In August 2019, Bayer announced positive results from its Phase III clinical trial of the drug vericiguat, which is used to treat patients with heart failure.

The trial showed that vericiguat can reduce the risk of cardiovascular death and hospitalization for heart failure, including stroke.